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A nonapeptide epitope contained in the 65-kD species of heat shock protein of
many mycobacterial species shares homology with a peptide on amammalian carti-
lage link protein (1), with four of the amino acids identical . Structures containing
this epitope, including proteoglycans extracted from human rheumatoid synovial
effusions (2), induce proliferation ofan arthritogenic, ratTlymphocyte line (3) that
hasbeen subdivided intotwoclones,A2band A2c, which, respectively, induce adju-
vant arthritis or suppress the developing andestablishedphases ofthis experimental
model of autoimmunity (4, 5) . Both clones proliferate in the presence of theepitope,
as do T lymphocytesfromsome rheumatoid arthritis patients (6), but it is not estab-
lished ifthe epitope plays a role in the pathogenesis of the arthritis . Administration
of therecombinant (r)65-kD shockproteinantigen intraperitoneally did notinduce
arthritis in rats, but rendered such rats resistant to further attempts to induce ar-
thritis with mycobacteria (1) or streptococcal cell walls (7) . It is known, however,
that adjuvant arthritis development requires the arthritogens to be administered in
an oil vehicle by either the intradermal or subcutaneous routes (reviewed in refer-
ence 8), and that the peptidoglycan component of the mycobacterial cell wall is es-
sential (8) .
Using high levels of the r65-kD protein in an oil vehicle, and even combining the
protein with low levels ofa synthetic, nonimmunogenic adjuvant, CP20961 (9), to
mimic the peptidoglycan portion of mycobacteria, we have been unable to induce
arthritis with the r65-kD shock protein, though the induction of resistance was
confirmed . At high levels, the synthetic adjuvant CP20961, which is known to be
arthritogenic (9), induced arthritis in rats rendered resistant to mycobacterial ar-
thritis by the r65-kD shock protein . Type II collagen-induced arthritis also devel-
oped in r65-kD protein-pretreated rats . These results strongly suggest that the r65-
kD shock protein produces an antigen-specific resistance to classical, mycobacterial
adjuvant arthritis, since it is much less effective at inhibiting the arthritis induced
by both CP20961 and type II collagen . Furthermore, the pathogenesis ofthe actual
adjuvant arthritis does not appear to involve the 65-kD protein .
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Materials and Methods
Adjuvant Arthritis.
￿
This was induced in female inbred Lewis rats (Olac, Bicester, UK)
(140-160 g at the beginning ofan experiment) by injection intradermally of250 Ag ofMycobac-
terium tuberculosis (M.tb.) (heat-killed human strains C, DT, and PN; Central Veterinary Labo-
ratory, Weybridge, UK) into the tail base. The M.tb. had been finely ground in a pestle and
mortar and suspended evenly in light paraffin oil at a concentration of 2.5 mg/ml. Develop-
ment of arthritis was measured by a scoring system assessing the symptoms at eight sites;
hind feet, fore feet, ears, eyes, tail, and nose on the basis, 0 = no signs to 4 = severe, so
that a total score of 32 was obtainable in each rat. In practice, arthritis development was
terminated at a score of 25, but in these experiments this score was rarely reached.
CP20961 Arthritis.
￿
This synthetic adjuvant (a lipoidal amine, Avridine; Pfizer, Groton,
CT [NN-dioctadecyl-N;N'-bis(2-hydroxyethyl)propanediamine]) induces an arthritis essen-
tially identical (9) to classical adjuvant arthritis. 5 mg of CP20961 in light paraffin oil (50
mg/ml) was injected intradermally into the tail base of Lewis rats, and the arthritis develop-
ment evaluated as described for adjuvant arthritis above.
Type H Collagen-inducedArthritis.
￿
This was induced in the Lewis rat (above) by injection
into the tail base of2 mg ofnative bovine type II collagen. The type II collagen was prepared
by standard procedures (10) and was prepared for injection at a concentration of 10 mg/ml
in a 1 :1 emulsion of 0.1 M acetic acid and IFA (Difco Laboratories Inc., Detroit, MI). Ar-
thritis was measured as for adjuvant arthritis above; however, the arthritis was mainly confined
to the hind feet, so that a score of 8 was frequently the maximum obtained.
Adoptive Transfer ofAdjuvant Arthritis with T Lymphocytes.
￿
The technique used was that de-
scribed by Taurog et al. (11). Essentially, lymph nodes and spleens were removed from Lewis
rats (described above) 10 d after injection ofM.tb; these were homogenized by use of a stomacher
(Seward Medical, London, UK) while suspended in RPMI 1640 supplemented with 10%
FCS and 1% penicillin/streptomycin (Gibco Laboratories, Paisley, Scotland). T lymphocytes
were obtained after passage over nylon wool columns, washed in medium, and suspended
at 2.5 x 106 ml ofmedium in 175-cmz flasks (Gibco Laboratories); these were incubated with
Con A (Sigma Chemical Co., Poole, UK) at a concentration of 2 .5 Pg/ml for 48 h at 37'C
in 5% CO2 in air. After incubation, T lymphocytes were washed in PBS, concentrated to
5 x 108 cells/ml, and immediately injected intravenously into naive, syngeneic female Lewis
rats (described above). Arthritis developed within 5-7 d and was assessed by the scoring method
above.
Administration ofr65-kD Antigen (Heat Shock Protein) to Rats.
￿
r65-kD antigen was dissolved
in PBS and subsequently mixed with an equal volume ofIFA (Difco Laboratories Inc.), and
emulsified to give emulsions containing 10-2,500 ug/ml. 0.1 ml ofthe emulsions was injected
intradermally into the tail base.
Expression and Purification ofthe r65-kD Mycobacterial Antigen.
￿
The procedures were essen-
tially those described previously (12). Briefly, the gene encoding the Mycobacterium leprae r65-
kD antigen was subcloned from a X gtll clone into the high copy number plasmid pUC8.
Escherichia coli(TG2) containing the recombinant plasmid expresses large amounts ofthe an-
tigen. Cultures of recombinant E. coli were grown overnight at 37 0C, harvested by centrifu-
gation, and resuspended in citrate-EDTA buffer. The bacteria were lysed by sonication, and
the particulate material was dissolved in phosphate-buffered 6 M urea. This material was
loaded onto a preparative polyacrylamide gel and subjected to electrophoresis overnight in
6 M urea. The 65-kD band was excised and homogenized in phosphate-buffered urea, filtered,
and precipitated by the addition of ammonium sulfate. The protein was dissolved in PBS,
dialyzed and filtered, and stored at -70°C before use.
Results and Discussion
Attempts to Induce Arthritis with r65-kD Protein.
￿
To determine whether r65-kD
mycobacterial antigen alone could induce adjuvant arthritis, rats were immunized
with the protein intradermally in IFA at doses of 1, 10, 50, and 250 lug. Control
rats, receiving M.tb. in oil developed arthritis after 10 d, whereas no arthritis wasw
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seen in anyofthe rats receivingr65-kD protein(Fig. 1 a). Interestingly, descriptions
of the histopathology of adjuvant arthritis (see reference 8) do not indicate a direct
attack on cartilage, where the shared epitope on the link protein exists. Our Lewis
strain of rat develops extensive bone destruction and periostitis, but the cartilage
is often left relatively undamaged.
We also attemptedto induce arthritisby administeringther65-kD protein in com-
bination with a suboptimal dose of the synthetic adjuvant CP20961, to mimic the
peptidoglycan adjuvant component of mycobacteria; this compound alone, at a 5-
mg level, induced arthritis similar to that seen with Mtb. (Fig. 1 b). At the lower
dose of 2 mg, a modest degree of arthritis was induced by CP20961 alone; in fact,
5 ofthe 10 rats so treateddevelopedsome degree ofarthritis. However, therats receiving
a combination of 2 mg CP20961 plus r65-kD protein failed to develop any symp-
toms of arthritis.
These results indicate that the r65-kD antigen, even when given by the optimal
routeof administration (subcutaneously) and at dosages that far exceed the amount
of protein that is administered when Mtb. is given, was unable to induce arthritis.
Furthermore, when added to a suboptimal dose of the arthritis-inducing adjuvant
CP20961, the r65-kD protein abrogated the induction of arthritis.
Resistance toArthritis.
￿
Rats that had been immunizedwith r65-kD proteinin IFA,
intradermally, were challenged 3-4 wk later either with M.tb. (Fig. 2 a) or CP20961
(Fig. 2 b) . Pretreatment with amounts of r65-kD protein as low as 1 Figsignificantly
protected against arthritis afterchallenge with M . tb.; only afewrats developed mild,
transient symptoms (Fig. 2 a), confirming earlier results (1). Interestingly, rats
pretreated intraperitoneally with 10 ttg r65-kD protein in saline developed full ar-
thritis when rechallenged with M .M.
Rats, however, that were pretreated intradermally with r65-kD protein and sub-
sequentlychallenged with 5 mg CP20961, all developedsymptoms ofarthritis, though
this was not as severe as that seen in naive rats given the CP20961 (Fig. 2 b); in
this experiment, rats rechallenged withM .tb. were againtotally resistantto arthritis.
It appears, therefore, that the r65-kD protein produces an antigen-specific resistance
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arthritis. In fact, the r65-kD protein abrogated the arthritogenic activity of the synthetic adjuvant at
the 2-mg level. Groups of 10 rats were used, and pretreatment with r65-kD protein was at 50 wg/rat
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(a) Rechallenge of r65-kD protein-pretreated rats with M.M. Rats pretreated with
r65-kD protein from 1-250Ftg were significantlyprotected against arthritis in comparison with
the control groupreceivingM.tb. Giving ther65-kD protein in saline intraperitoneally, however,
was not protective. Groups of five rats were used; groupmeans are plotted. (b) Rechallenge of
r65-kD protein protected rats with the synthetic adjuvant, CP20961. A level of 50 F+g r65-kD
proteinprotected rats againstMtb.-induced arthritis; however, 5mg ofCP20961 inducedsignificant
arthritis in similarly pretreated rats, though this was not as severe as in the CP20961 control
group. Groups of 10 rats were used; group means are plotted.
to the arthritis induced by M .tb., even at a 1-Ag level, but is markedly less effective
against CP20961 arthritis. Interestingly, resistance to adjuvant arthritis can be in-
duced by preadministration of very low doses of M.tb., and such resistance is also
overridden by the administration of CP20961 (13).
Effect ofr65-kD Proteinon Type II Collagen-induced Arthritis.
￿
Rats were treatedwith
20 Ag r65-kD protein 3-4 wk before challenge with type II collagen. The results
are presented in Table I, andshow the data forday 23, at the peak ofarthritis devel-
opment. Compared with control rats, fewer r65-kD-pretreated rats developed type
II collagen arthritis, and the symptoms tended to be milder, but, as with CP20961
arthritis, thecollagen-induced arthritis was mildly reduced, though not prevented,
by the r65-kD protein. This contrasts markedly with the virtual total inhibition of
mycobacterial adjuvant arthritis, and again emphasizes the antigen-specific nature
of the influenceofthe r65-kD protein on arthritisdevelopment. Themild inhibition
oftheCP20961 andtype II collagen arthritisis intriguing, nonetheless, andrequires
further investigation.
6
10 rats were used in each group, andthe numberswith a given score areshown
over the range, 0 = no symptoms to 8 = severe symptoms in both hind feet.
No rats achieved maximum scores in this experiment. r65-kD protein reduced
the incidence and severity of arthritis, but did not totally prevent it.
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Resistance Induced by r65-kD Protein is Overcome by Transfer ofArthritogenic T Cells.
￿
A
CD4' population of helper T lymphocytes is known to be responsible for the in-
duction of arthritis by MA. and CP20691, from both adoptive transfer experiments
(11, 14) and the use of anti-CD4 mAbs (14). To test whether resistance to adjuvant
arthritis was due to suppression of the activity, or inhibition of clonal expansion of
these autoreactive CD4+ T lymphocytes, we transferred 5 x 108 arthritogenic T
lymphocytes to rats pretreated with r65-kD protein (Fig. 3). The pretreated rats
developed severe arthritis when giventhe arthritogenic T lymphocytes, comparable
with that seen with age-matched controls receiving similar Tlymphocytes, whereas
pretreated rats that were rechallenged with M.tb. did not develop arthritis. Thus,
the prior administration of r65-kD protein does not result in the generation of a
population of cells that inhibits the activity of arthritogenic T lymphocytes, but,
presumably, prevents them being developed in the first place. van den Broek et al.
(7)have, in fact, demonstrated that resistance induced by the r65-kD protein resides
within a T lymphocyte population, since such cells transfer resistance to naive rats.
Summary
A recombinant (r)65-kD protein from Mycobacterium lelbrae, at levels far in excess
of those present in whole mycobacteria, was unable to induce arthritis. Even when
combined with asyntheticadjuvant, CP20961, to mimicthe peptidoglycanadjuvant
component of the mycobacterial cell wall, the r65-kD protein failed to induce ar-
thritis. Pretreatment with as little as 1 ug r65-kD protein protected rats against ar-
thritis induced by M. tubuculosis, but this r65-kD protein was markedly less able to
protect againstarthritis induced by the synthetic adjuvant, CP20961, or type II col-
lagen. The r65-kD protein appears, therefore, to produce an antigen-specific pro-
tection against arthritis induced by bacterial cell walls containing the 65-kD pro-
tein. Such protection can be overcome, however, by arthritogenic T lymphocytes,
suggesting that protection occurs by preventing clonal proliferation of autoreactive
T lymphocytes that areinducedby theadjuvant properties ofmycobacterial cell walls.
How the r65-kD protein abrogates this particular adjuvant activity, and the nature
of the arthritogenic self antigen(s), remain to be elucidated.344
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